CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report

CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Case Rep
Main Authors: Urbantat, Ruth M., Popper, Valentin, Menschel, Elisabeth, Pfeilstöcker, Michael, Forjan, Ernst, Nader, Alexander, Sieghart, Catherine R., Keil, Felix, Koller, Elisabeth
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077323/
https://ncbi.nlm.nih.gov/pubmed/33936618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3909
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados